Research overview
What is Retatrutide?
Retatrutide (LY3437943) is designed to stimulate three hormone receptors: GIP, GLP-1, and glucagon. It should not be conflated with tirzepatide, which targets GIP and GLP-1, or with mazdutide, which targets GLP-1 and glucagon. An investigational clinical product is not equivalent to a supplier vial.
What has research examined?
A 338-participant placebo-controlled phase 2 trial reported dose-group-dependent weight change at studied endpoints, with adverse effects predominantly gastrointestinal. Later phase 3 programs are product-specific and do not establish FDA approval. FDA has issued concerns and enforcement action regarding unapproved retatrutide products marketed outside the clinical development setting.
A trial effect cannot be assigned to an unverified research powder or converted into dosing advice. This page gives no treatment, amount, syringe, or preparation instruction.
Research references
- Triple-hormone-receptor agonist retatrutide for obesity: phase 2 trialNew England Journal of Medicine
- FDA concerns with unapproved GLP-1 drugs for weight lossU.S. Food and Drug Administration
Calculation boundary
FDA identifies retatrutide as an unapproved GLP-1 drug and has challenged marketing/compounding of retatrutide products. A syringe measurement diagram would not establish regulated product quality or authorized use.